CD19 and cancer: A study reported that the unintentional transduction of a single leukemic B cell during anti-CD19 CAR T cell manufacture led to resistance against the CAR T cell therapy by masking the CD19 epitope, resulting in cancer relapse and the death of the patient enrolled in a phase 1 trial (26).